Table 3 Specifications related to infants born to pregnant women with HIV identified in the pilot study
From: Prevention of mother-to-child HIV transmission program in Iran
Variable | Frequency | % | |
|---|---|---|---|
Type of delivery | Cesarean section | 63 | 85.1 |
NVD | 4 | 5.4 | |
Pregnant at the moment of the study | 7 | 9.5 | |
Outcome of pregnancy | Abortion | 2 | 2.6 |
Live birth | 67 | 88.2 | |
Pregnant at the moment of the study | 7 | 9.2 | |
Newborn prophylaxis | Yes | 66 | 95.5 |
No | 2 | 3 | |
Unknown | 1 | 1.5 | |
Feeding with formulated milk | Yes | 67 | 100 |
No | 0 | 0 | |
PCR in week 6–8 | Yes | 58 | 86.6 |
No | 9 | 13.4 | |
HIV testing in month 18 (27 infants) | Yes | 20 | 74.1 |
No | 7 | 24.9 | |
Prophylaxis situation in infants | Completed | 67 | 100 |
Incomplete | 0 | 0 | |
HIV positive infant | Yes | 1 | 1.5 |
No | 66 | 98.5 | |
Infant growth status | Normal range | 60 | 78.9 |
Abnormal range | 3 | 3.9 | |
Unknown | 4 | 5.3 | |
Infant vaccination status | Per protocol | 59 | 77.6 |
With some error | 4 | 5.3 | |
Unknown | 4 | 5.3 |